

# Tillotts Pharma Transfers of Value in 2020 to Austrian Healthcare Professionals and Healthcare Organisations

COC - ORDINANCE ON ARTICLE 9 - STANDARDIZED TEMPLATE FOR THE DOCUMENTATION OF DATA TO BE DISCLOSED

DATA DOCUMENTATION - ARTICLE 9 COC (TRANSPARENCY)

Reporting period (calendar year): 2019

Date of publication: June 2020

	Name  (cf. Article 9.4 CoC)	Practice or business address			Where available: physician number commercial register number, association register number  (cf. Article 9.4 CoC)	Financial or material donations as well as subsidies  (cf. Article 9.4b 1) CoC)	Transfers of value granted in connection with events (cf. Article 9.4a 1) (i), (ii) CoC and/or Article 9.4b 2) (i), (ii), (iii) CoC)			Fees for services rendered and consulting provided (cf. Article 9.4a 2) CoC and/or Article 9.4b 3) CoC)		TOTAL	
		(cf. Article 9.4 CoC)	(cf. Article 9.4 CoC)	(cf. Article 9.4 CoC)			(cf. Article 9.4 CoC)	Support of institutions or third parties appointed by such organizations for implementing the event	Admission and attendance fees	Travel costs and costs for overnight accomodation	Fees		Expenses
HCPs	INDIVIDUAL NAMED DISCLOSURE FOR HEALTHCARE PROFESSIONALS [one row per HCP, with all transfers of value for the reporting period summed up]												
						N/A	N/A						
	AGGREGATE DISCLOSURE FOR HEALTHCARE PROFESSIONALS												
	Total amount					N/A	N/A						
	Total number of recipients of transfers of value by subtype					N/A	N/A						
% of total transfers of value to all HCP recipients by subtype					N/A	N/A							
HCIs	INDIVIDUAL NAMED DISCLOSURE FOR HEALTHCARE INSTITUTIONS [one row per HCI, with all transfers of value for the reporting period summed up]												
	European Crohn's and Colitis Organisation	Vienna	Austria	Ungargasse 6/13 1030 Vienna, Austria		26'440 EUR	11'624,20 EUR	15'860 EUR				53'924,20 EUR	
	United European Gastroenterology	Vienna	Austria	Wickenburggasse 1 1080 Vienna Austria		10'000 EUR		875 EUR				10'875 EUR	
	AGGREGATE DISCLOSURE FOR HEALTHCARE INSTITUTIONS												
	Total amount												
Total number of recipients of transfers of value by subtype													
% of total transfers of value to all HCI recipients by subtype													
R & D	AGGREGATE DISCLOSURE FOR RESEARCH & DEVELOPMENT												
	Transfers of value granted in connection with research & development, cf. Article 9.3a CoC											Total	

The rules referred to are those set out in the Pharmig Code of Conduct (CoC)  
HCP = healthcare professional within the meaning of Article 3 CoC  
HCI = healthcare establishments, organizations or institutions within the meaning of Article 8.4 CoC  
R&D = research and development

## **Methodological Notes**

### **Disclosure by Tillotts Pharma of payments to Austrian healthcare professionals and healthcare organisations in 2020**

Article 9 of the Pharmig Code of Conduct (Pharmig Code) mandates the public disclosure in 2021 of certain transfers of value made during 2020 to Austrian healthcare professionals and healthcare organisations. The disclosure data will be published on the website of Tillotts Pharma, [www.tillotts.com](http://www.tillotts.com). The disclosure requirements are set forth in Section 2 of the Pharma Cooperation Code.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding.

#### **VAT**

VAT is excluded from the transfers of value.

#### **Currency**

All disclosures are made in Euros (EUR). Where the original payment was made in another currency, the sum was converted to Euros at the 2020 average annual exchange rate published by the European Central Bank ([www.ecb.europa.eu/](http://www.ecb.europa.eu/)).

#### **Date of Payment**

All disclosures are based on the date of payment to the recipient, irrespective of the date of invoice or the date of the underlying activity or event.

#### **Consolidated Disclosures of the Corporate Group and Cross-border Payments**

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company.

#### **Data Protection**

##### **Consent to disclose data**

In countries where it is required by applicable data protection laws, Tillotts has taken all reasonable steps to obtain consents from the HCPs, and HCOs, as applicable, to publicly disclose payments and other transfers of value. In accordance with EFPIA guidance, partial consents are not acceptable. If consent is not provided, the data will be reported on an aggregate level only.

##### **Consent collection and withdrawal**

Tillotts respects applicable data protection laws. If a stakeholder withdraws the provided consent, Tillotts will adjust the publication accordingly within a reasonable time.

**Data included**

The data disclosed by Tillotts Pharma is consistent with the requirements of the Pharmig Code. The data can be categorised as follows:

***Financial or material donations as well as subsidies***

Disclosed data includes the payment of membership fees paid to healthcare organisations for Tillotts Pharma and/or Tillotts Pharma staff and, when applicable, other non-HCP individuals.

***Transfers of value granted in connection with events***

Disclosed data includes payments to healthcare organisations that represent a contribution of costs related to an event. Such data includes the following types of payments paid to the healthcare organisations or to a third party appointed by the healthcare organisation to organize an event: fees for exhibition/booth space at an event; fees for event exhibition badges and event registration fees; fees related to advertising at an event; and sponsorship fees related to an event or satellite symposium at an event.